Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 7/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.33 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19615346 | 0.84 | GAA (0.37) | GAA | |
| SCHEMBL22437529 | 0.82 | CSNK2A2 (0.37) | CSNK2A1CSNK2A2CSNK2BCSNK2A3GAA | |
| SCHEMBL22437415 | 0.82 | GAA (0.34) | GAA | |
| SCHEMBL19635866 | 0.81 | IDO1 (0.33) | CSNK2A1CSNK2A2CSNK2BCSNK2A3IDO1 | |
| SCHEMBL3798741 | 0.79 | GAA (0.44) | GAAIDO1 | |
| SCHEMBL19616041 | 0.77 | SMN1; SMN2 (0.36) | — | |
| SCHEMBL19618982 | 0.76 | IDO1 (0.32) | CSNK2A1CSNK2A2CSNK2BCSNK2A3IDO1 | |
| SCHEMBL4163341 | 0.75 | CSNK2A1 (0.35) | CSNK2A1CSNK2A2CSNK2BCSNK2A3GAA | |
| SCHEMBL14044114 | 0.75 | — | — | |
| SCHEMBL22437451 | 0.74 | CSNK2A2 (0.37) | CSNK2A1CSNK2A2CSNK2BCSNK2A3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152041-B2 | Macrocyclic fluorine substituted indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-11891404-B2 | Substituted macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-06 | — | — | US | disclosed |
| CN-111757884-B | Substituted macrocyclic indole derivatives | 拜耳股份公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230250109-A1 | MACROCYCLIC ETHER CONTAINING INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| EP-4178677-A1 | MACROCYCLIC ETHER CONTAINING INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN Pharmaceutica NV (BE) | 2023-05-17 | — | — | EP | disclosed |
| US-20230112244-A1 | SUBSTITUTED MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| CN-115776888-A | Macrocyclic ether containing indole derivatives as MCL-1 inhibitors | 詹森药业有限公司 | 2023-03-10 | — | — | CN | disclosed |
| US-11492358-B1 | Macrocyclic indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11478451-B1 | Macrocyclic chlorine substituted indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-25 | — | — | US | disclosed |
| US-11478451-B1 | Macrocyclic chlorine substituted indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-25 | — | — | US | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20210079018-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-18 | — | — | US | disclosed |
| US-20210079018-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-18 | — | — | US | disclosed |
| CN-111757884-A | Substituted macrocyclic indole derivatives | 拜耳股份公司 | 2020-10-09 | — | — | CN | disclosed |
| EP-3710449-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS, FOR USE IN THE TREATMENT OF CANCER | The Broad Institute, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3710448-A1 | MACROCYCLIC CHLORINE SUBSTITUTED INDOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2020-09-23 | — | — | EP | disclosed |
| EP-3710456-A1 | MACROCYCLIC INDOLE DERIVATIVES | The Broad Institute, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3710447-A1 | ARYL ANNULATED MACROCYCLIC INDOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2020-09-23 | — | — | EP | disclosed |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-03-19 | — | — | US | disclosed |
| WO-2017198341-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230112244-A1 | SUBSTITUTED MACROCYCLIC INDOLE DERIVATIVES | FOXM1, CCND2, CCNI | CSNK2A1 809/4885CSNK2A2 1001/4885CSNK2B 1018/4885 |
| US-12152041-B2 | Macrocyclic fluorine substituted indole derivatives | FOXM1, CCNT2, CCND2 | CSNK2A1 1702/4885CSNK2A2 1964/4885CSNK2B 1993/4885 |
| US-11891404-B2 | Substituted macrocyclic indole derivatives | FOXM1, CCND2, CCNI | CSNK2A1 809/4885CSNK2A2 1001/4885CSNK2B 1018/4885 |
| US-20230250109-A1 | MACROCYCLIC ETHER CONTAINING INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | MCL1, BAK1, BCL2L1 | CSNK2A1 2398/4885CSNK2A2 2656/4885CSNK2B 2769/4885 |
| US-11492358-B1 | Macrocyclic indole derivatives | CCND2, CCNT2, IDO1 | CSNK2A1 856/4885CSNK2A2 986/4885CSNK2B 1077/4885 |
| US-10981932-B2 | Macrocyclic indole derivatives | CCND2, IDO1, CCNT2 | CSNK2A1 980/4885CSNK2A2 1074/4885CSNK2B 1154/4885 |
| US-20210079018-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES | FOXM1, CCNT2, CCND2 | CSNK2A1 1702/4885CSNK2A2 1964/4885CSNK2B 1993/4885 |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | CCND2, CCNA1, CCNT2 | CSNK2A1 841/4885CSNK2A2 995/4885CSNK2B 1110/4885 |
| US-11478451-B1 | Macrocyclic chlorine substituted indole derivatives | CCNT2, CCNL2, CCND2 | CSNK2A1 457/4885CSNK2A2 605/4885CSNK2B 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.